Role of “old” pharmacological agents in the treatment of Cushing’s syndrome

A. G. Ambrogio, F. Cavagnini

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Despite recent advances in the management of endogenous Cushing’s syndrome (CS), its treatment remains a challenge. When surgery has been unsuccessful or unfeasible as well in case of recurrence, the “old” pharmacological agents represent an important alternative for both ACTH-dependent and independent hypercortisolism. Especially in the latter, the advent of novel molecules directly targeting ACTH secretion has not outweighed the “old” drugs, which continue to be largely employed and have recently undergone a reappraisal. This review provides a survey of the “old” pharmacological agents in the treatment of CS.

Original languageEnglish
Pages (from-to)957-965
Number of pages9
JournalJournal of Endocrinological Investigation
Volume39
Issue number9
DOIs
Publication statusPublished - Sep 1 2016

Fingerprint

Cushing Syndrome
Pharmacology
Adrenocorticotropic Hormone
Recurrence
Pharmaceutical Preparations

Keywords

  • Adrenal blocking agents
  • Cabergoline
  • Cushing’s disease
  • Cushing’s syndrome
  • Efficacy
  • Medical therapy
  • Mifepristone
  • Pasireotide
  • Side effects

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Role of “old” pharmacological agents in the treatment of Cushing’s syndrome. / Ambrogio, A. G.; Cavagnini, F.

In: Journal of Endocrinological Investigation, Vol. 39, No. 9, 01.09.2016, p. 957-965.

Research output: Contribution to journalReview article

@article{8e4906c5a8e54f5d85c15c59ae8b3431,
title = "Role of “old” pharmacological agents in the treatment of Cushing’s syndrome",
abstract = "Despite recent advances in the management of endogenous Cushing’s syndrome (CS), its treatment remains a challenge. When surgery has been unsuccessful or unfeasible as well in case of recurrence, the “old” pharmacological agents represent an important alternative for both ACTH-dependent and independent hypercortisolism. Especially in the latter, the advent of novel molecules directly targeting ACTH secretion has not outweighed the “old” drugs, which continue to be largely employed and have recently undergone a reappraisal. This review provides a survey of the “old” pharmacological agents in the treatment of CS.",
keywords = "Adrenal blocking agents, Cabergoline, Cushing’s disease, Cushing’s syndrome, Efficacy, Medical therapy, Mifepristone, Pasireotide, Side effects",
author = "Ambrogio, {A. G.} and F. Cavagnini",
year = "2016",
month = "9",
day = "1",
doi = "10.1007/s40618-016-0462-4",
language = "English",
volume = "39",
pages = "957--965",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Springer International Publishing",
number = "9",

}

TY - JOUR

T1 - Role of “old” pharmacological agents in the treatment of Cushing’s syndrome

AU - Ambrogio, A. G.

AU - Cavagnini, F.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Despite recent advances in the management of endogenous Cushing’s syndrome (CS), its treatment remains a challenge. When surgery has been unsuccessful or unfeasible as well in case of recurrence, the “old” pharmacological agents represent an important alternative for both ACTH-dependent and independent hypercortisolism. Especially in the latter, the advent of novel molecules directly targeting ACTH secretion has not outweighed the “old” drugs, which continue to be largely employed and have recently undergone a reappraisal. This review provides a survey of the “old” pharmacological agents in the treatment of CS.

AB - Despite recent advances in the management of endogenous Cushing’s syndrome (CS), its treatment remains a challenge. When surgery has been unsuccessful or unfeasible as well in case of recurrence, the “old” pharmacological agents represent an important alternative for both ACTH-dependent and independent hypercortisolism. Especially in the latter, the advent of novel molecules directly targeting ACTH secretion has not outweighed the “old” drugs, which continue to be largely employed and have recently undergone a reappraisal. This review provides a survey of the “old” pharmacological agents in the treatment of CS.

KW - Adrenal blocking agents

KW - Cabergoline

KW - Cushing’s disease

KW - Cushing’s syndrome

KW - Efficacy

KW - Medical therapy

KW - Mifepristone

KW - Pasireotide

KW - Side effects

UR - http://www.scopus.com/inward/record.url?scp=84983020740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983020740&partnerID=8YFLogxK

U2 - 10.1007/s40618-016-0462-4

DO - 10.1007/s40618-016-0462-4

M3 - Review article

VL - 39

SP - 957

EP - 965

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 9

ER -